Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa